Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS207 Combined With Platinum-based Doublet Chemotherapy in Stage II-III NSCLC
NCT06944470Phase 2Active, not recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- May 2025
- Primary completion
- Apr 2027
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of JS207 in non-small cell lung cancer (NSCLC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started May 2025; status: active, not recruiting.
02
Drugs
JS207
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06944470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06944470.